Showing 1 - 14 results of 14 for search 'Shengxiang REN', query time: 0.05s
Refine Results
-
1
Updates to the 2024 CSCO advanced non-small cell lung cancer guidelines by Jiale Wang, Tianyu Qiu, Shengxiang Ren
Published 2025-02-01
Article -
2
-
3
-
4
Fibronectin promotes tumor angiogenesis and progression of non-small-cell lung cancer by elevating WISP3 expression via FAK/MAPK/ HIF-1α axis and activating wnt signaling pathway by Fei Zhou, Jianguo Sun, Lingyun Ye, Tao Jiang, Wei Li, Chunxia Su, Shengxiang Ren, Fengying Wu, Caicun Zhou, Guanghui Gao
Published 2023-07-01
Article -
5
CXCR1+ neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant non-small-cell lung cancer by Haowei Wang, Anwen Xiong, Xiaoxia Chen, Junhong Guo, Zhuoran Tang, Chunyan Wu, Shengxiang Ren, Caicun Zhou, Jian Chen, Likun Hou, Tao Jiang
Published 2024-12-01
Article -
6
Induction immunochemotherapy followed by definitive chemoradiotherapy for unresectable locally advanced non‐small cell lung cancer: a multi‐institutional retrospective cohort study... by Leilei Wu, Bo Cheng, Xiaojiang Sun, Zhenshan Zhang, Jingjing Kang, Yun Chen, Qinghua Xu, Shuangyan Yang, Yujie Yan, Shengxiang Ren, Caicun Zhou, Yaping Xu
Published 2024-03-01
Article -
7
Targeting focal adhesion kinase boosts immune response in KRAS/LKB1 co-mutated lung adenocarcinoma via remodeling the tumor microenvironment by Meng Qiao, Fei Zhou, Xinyu Liu, Tao Jiang, Haowei Wang, Xuefei Li, Chao Zhao, Lei Cheng, Xiaoxia Chen, Shengxiang Ren, Zaiqi Wang, Caicun Zhou
Published 2024-01-01
Article -
8
Interleukin-10 induces expression of CD39 on CD8+T cells to potentiate anti-PD1 efficacy in EGFR-mutated non-small cell lung cancer by Lei Cheng, Caicun Zhou, Tao Jiang, Fei Zhou, Shengxiang Ren, Hongcheng Liu, Xinyu Liu, Xiaoxia Chen, Xuefei Li, Chao Zhao, Meng Qiao, Haowei Wang, Yijun Jia
Published 2022-12-01
Article -
9
-
10
Genomic correlates of the response to first-line PD-1 blockade plus chemotherapy in patients with advanced non-small-cell lung cancer by Tao Jiang, Jian Chen, Haowei Wang, Fengying Wu, Xiaoxia Chen, Chunxia Su, Haiping Zhang, Fei Zhou, Ying Yang, Jiao Zhang, Huaibo Sun, Henghui Zhang, Caicun Zhou, Shengxiang Ren, Peifang Wei
Published 2024-09-01
Article -
11
A phase II study on Mefatinib as first‐line treatment of patients with advanced non‐small‐cell lung cancer harboring uncommon EGFR mutations by Pingli Wang, Liming Cao, Panwen Tian, Shengxiang Ren, Liyun Miao, Chengzhi Zhou, Yun Fan, Yuping Li, Dongqing Lv, Xin Zhao, Mei Yang, Chaonan Zhu, Bing Yu, June Xu, Yong Song, Kai Wang
Published 2023-09-01
Article -
12
Efficacy and safety of local ablative therapy for patients with NSCLC and coexisting interstitial lung disease by Chuchu Shao, Xinxin Zhi, Shiqi Mao, Leilei Wu, Jia Yu, Shuo Yang, Wanying Wang, Keyi Jia, Libo Luo, Xinyu Liu, Tao Jiang, Fei Zhou, Bin Chen, Lei Wang, Guanghui Gao, Jingyun Shi, Xiaoxia Chen, Fengying Wu, Shengxiang Ren
Published 2024-04-01
Article -
13
First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial by Ying Liu, Jia Fan, Jun Zhao, Tianshu Liu, Caicun Zhou, Shengxiang Ren, Ying Cheng, Caigang Liu, Xicheng Wang, Sheng Hu, Yufeng Cheng, Yueyin Pan, Shegan Gao, Yalun Li, Bao-Hui Han, Jifeng Feng, Shanyong Yi, Shanzhi Gu, Yongzhong Luo, Huijie Duan, Shuni Wang, Xinfeng Yang
Published 2024-02-01
Article -
14
Chinese expert consensus recommendations for the administration of immune checkpoint inhibitors to special cancer patient populations by Jun Wang, Bicheng Zhang, Ling Peng, Xiufeng Liu, Jianguo Sun, Chunxia Su, Huijuan Wang, Zheng Zhao, Lu Si, Jianchun Duan, Hongmei Zhang, Mengxia Li, Bo Zhu, Li Zhang, Jin Li, Jun Guo, Rongcheng Luo, Wensheng Qiu, Dingwei Ye, Qian Chu, Jiuwei Cui, Xiaorong Dong, Yun Fan, Quanli Gao, Ye Guo, Zhiyong He, Wenfeng Li, Gen Lin, Lian Liu, Yutao Liu, Haifeng Qin, Shengxiang Ren, Xiubao Ren, Yongsheng Wang, Junli Xue, Yunpeng Yang, Zhenzhou Yang, Lu Yue, Xianbao Zhan, Junping Zhang, Jun Ma, Shukui Qin, Baocheng Wang
Published 2023-07-01
Article